Literature DB >> 24668120

Clinically high-risk prostate cancer patients comprise a relevant number of cancers with overall favorable tumor characteristics.

M Musch1, J Pluemer, U Roggenbuck, V Klevecka, D Kroepfl.   

Abstract

PURPOSE: We hypothesized that a relevant number of patients with clinically high-risk prostate cancer (PCA) indeed harbor overall favorable tumor characteristics (OFTC) (i.e., pT2a-c and Gleason score ≤3 + 4 = 7 and pN0/X) and that in these patients radical prostatectomy (RP) alone is most likely curative.
METHODS: Between June 1, 1997, and October 31, 2011, 2,346 patients with biopsy-detected PCA underwent RP. According to D'Amico, 1,767 patients presented low-/intermediate-risk PCA, and 579 presented high-risk PCA. We compared the incidence of OFTC between low-/intermediate-risk and high-risk patients, and between high-risk patients with different risk factor constellations. Furthermore, overall survival (OS), cancer-specific survival (CSS) and biochemical progression-free survival (BFS) were calculated for low-/intermediate-risk and high-risk patients with and without OFTC.
RESULTS: High-risk patients were less likely to harbor OFTC (17.3 vs. 58.2 %; p < 0.001). That means, however, that nearly one in five patients with clinically high-risk PCA indeed had OFTC. Particularly, the subgroup with PSA >20 ng/ml or cT2c-3 tumor as sole high-risk factor showed a considerable proportion of OFTC in 30.2 and 26.1 % of cases, respectively. While the entire high-risk group had shorter OS, CSS and BFS than the low-/intermediate-risk group, high-risk patients with OFTC had comparably good OS, CSS and BFS as low-/intermediate-risk patients with OFTC.
CONCLUSIONS: Nearly, one in five patients assumed to have high-risk PCA indeed had OFTC. Particularly, patients with PSA >20 ng/ml or cT2c-3 tumor as sole high-risk factor were often misclassified. However, these misclassified patients achieve excellent survival and have a reasonable chance of cure with RP alone.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24668120     DOI: 10.1007/s00345-014-1274-9

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  24 in total

1.  Guideline for the management of clinically localized prostate cancer: 2007 update.

Authors:  Ian Thompson; James Brantley Thrasher; Gunnar Aus; Arthur L Burnett; Edith D Canby-Hagino; Michael S Cookson; Anthony V D'Amico; Roger R Dmochowski; David T Eton; Jeffrey D Forman; S Larry Goldenberg; Javier Hernandez; Celestia S Higano; Stephen R Kraus; Judd W Moul; Catherine M Tangen
Journal:  J Urol       Date:  2007-06       Impact factor: 7.450

2.  NCCN clinical practice guidelines in oncology: prostate cancer.

Authors:  James Mohler; Robert R Bahnson; Barry Boston; J Erik Busby; Anthony D'Amico; James A Eastham; Charles A Enke; Daniel George; Eric Mark Horwitz; Robert P Huben; Philip Kantoff; Mark Kawachi; Michael Kuettel; Paul H Lange; Gary Macvicar; Elizabeth R Plimack; Julio M Pow-Sang; Mack Roach; Eric Rohren; Bruce J Roth; Dennis C Shrieve; Matthew R Smith; Sandy Srinivas; Przemyslaw Twardowski; Patrick C Walsh
Journal:  J Natl Compr Canc Netw       Date:  2010-02       Impact factor: 11.908

3.  Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.

Authors:  John F Ward; Jeffrey M Slezak; Michael L Blute; Erik J Bergstralh; Horst Zincke
Journal:  BJU Int       Date:  2005-04       Impact factor: 5.588

4.  Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer.

Authors:  Stephen A Boorjian; R Jeffrey Karnes; Rosalia Viterbo; Laureano J Rangel; Eric J Bergstralh; Eric M Horwitz; Michael L Blute; Mark K Buyyounouski
Journal:  Cancer       Date:  2011-01-10       Impact factor: 6.860

5.  Radical prostatectomy for cT3-4 disease: an evaluation of the pathological outcomes and patterns of care for adjuvant radiation in a national cohort.

Authors:  David Schreiber; Justin Rineer; Sonal Sura; Ervin Teper; Tom Nabhani; Peter Han; David Schwartz; Kwang Choi; Marvin Rotman
Journal:  BJU Int       Date:  2010-11-18       Impact factor: 5.588

6.  Radical prostatectomy for high-risk clinically localized prostate cancer: a prospective single institution series.

Authors:  Anthony J Koupparis; Jeremy P Grummet; Antonio Hurtado-Coll; Robert H Bell; Nicholas Buchan; S Larry Goldenberg; Martin E Gleave
Journal:  Can Urol Assoc J       Date:  2011-03-01       Impact factor: 1.862

7.  Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy.

Authors:  Ofer Yossepowitch; Scott E Eggener; Angel M Serio; Brett S Carver; Fernando J Bianco; Peter T Scardino; James A Eastham
Journal:  Eur Urol       Date:  2007-10-12       Impact factor: 20.096

8.  Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations.

Authors:  P C Walsh; H Lepor; J C Eggleston
Journal:  Prostate       Date:  1983       Impact factor: 4.104

9.  High-risk prostate cancer in the United States, 1990-2007.

Authors:  Matthew R Cooperberg; Janet Cowan; Jeannette M Broering; Peter R Carroll
Journal:  World J Urol       Date:  2008-03-28       Impact factor: 4.226

10.  Substratification of high-risk localised prostate cancer treated by radical prostatectomy.

Authors:  Michele Lodde; François Harel; Louis Lacombe; Yves Fradet
Journal:  World J Urol       Date:  2008-03-28       Impact factor: 4.226

View more
  2 in total

1.  Heterogeneous oncologic outcomes according to surgical pathology in high-risk prostate cancer: implications for better risk stratification and preoperative prediction of oncologic outcomes.

Authors:  Seung-Kwon Choi; Myungsun Shim; Myong Kim; Myungchan Park; Sangmi Lee; Cheryn Song; Hyung-Lae Lee; Hanjong Ahn
Journal:  J Cancer Res Clin Oncol       Date:  2017-05-18       Impact factor: 4.553

2.  Time to Disease Recurrence Is a Predictor of Metastasis and Mortality in Patients with High-risk Prostate Cancer Who Achieved Undetectable Prostate-specific Antigen Following Robot-assisted Radical Prostatectomy.

Authors:  Do Kyung Kim; Kyo Chul Koo; Kwang Suk Lee; Yoon Soo Hah; Koon Ho Rha; Sung Joon Hong; Byung Ha Chung
Journal:  J Korean Med Sci       Date:  2018-10-16       Impact factor: 2.153

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.